Literature DB >> 10961174

Flow cytometric immunophenotyping of serous effusions and peritoneal washings: comparison with immunocytochemistry and morphological findings.

B Risberg1, B Davidson, H P Dong, J M Nesland, A Berner.   

Abstract

AIM: To evaluate immunophenotyping by means of flow cytometry as a complementary method for the detection of malignant cells in serous effusions and peritoneal washings.
MATERIAL AND METHODS: Frozen samples of 49 fresh serous effusions and peritoneal washings were analysed by flow cytometry, using monoclonal antibodies against CD45, Ber-EP4, and N-cadherin. Results were compared with smear and cell block morphology, as well as immunocytochemistry on paraffin wax embedded cell blocks.
RESULTS: Seventeen specimens were cytologically diagnosed as malignant, whereas 25 were interpreted as benign. The remaining seven specimens were diagnosed as indeterminate or suspicious for malignancy. Ber-EP4 positive cells were detected in 16 of the 17 cytologically malignant effusions, as well as in five of seven suspicious cases and five of 25 specimens with benign cytology. In the latter group, three specimens showed atypical or malignant cell groups that were missed in routine morphological evaluation. In two additional samples, obtained from patients with benign and borderline ovarian tumours, Ber-EP4 positive cells showed benign or mildly atypical features, and were interpreted as exfoliated benign or borderline malignant epithelial cells of tubal origin, or as endosalpingiosis. All five Ber-EP4 positive indeterminate specimens showed atypical or malignant cells on re-evaluation, and were Ber-EP4 positive in four of five cases using immunohistochemistry in cell block sections. Large numbers of CD45 positive and relatively few N-cadherin positive cells were detected in most specimens with the use of flow cytometry, when compared with morphological evaluation.
CONCLUSIONS: Flow cytometry is a rapid and highly effective method for the evaluation of effusions and peritoneal washings. The detection of Ber-EP4 positive cells using flow cytometry is strongly indicative of the presence of carcinoma cells in effusions and peritoneal washings. Although false positives are relatively infrequent, all specimens should be carefully evaluated morphologically to prevent the diagnosis of benign epithelial clusters as malignant.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10961174      PMCID: PMC1731234          DOI: 10.1136/jcp.53.7.513

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  31 in total

Review 1.  Cadherin cell adhesion receptors as a morphogenetic regulator.

Authors:  M Takeichi
Journal:  Science       Date:  1991-03-22       Impact factor: 47.728

2.  Spatial and temporal expression pattern of N-cadherin cell adhesion molecules correlated with morphogenetic processes of chicken embryos.

Authors:  K Hatta; S Takagi; H Fujisawa; M Takeichi
Journal:  Dev Biol       Date:  1987-03       Impact factor: 3.582

3.  Flow cytometric identification of cancer cells in effusions with Ca1 monoclonal antibody.

Authors:  B Czerniak; P R Papenhausen; F Herz; L G Koss
Journal:  Cancer       Date:  1985-06-15       Impact factor: 6.860

4.  Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers.

Authors:  B Davidson; B Risberg; G Kristensen; G Kvalheim; E Emilsen; A Bjåmer; A Berner
Journal:  Virchows Arch       Date:  1999-07       Impact factor: 4.064

5.  Efficiency of Ber-EP4 antibody for isolating circulating epithelial tumor cells before RT-PCR detection.

Authors:  A Sabile; M Louha; E Bonte; K Poussin; G Vona; A Mejean; Y Chretien; L Bougas; B Lacour; F Capron; A Roseto; C Bréchot; P Paterlini-Bréchot
Journal:  Am J Clin Pathol       Date:  1999-08       Impact factor: 2.493

6.  Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial.

Authors:  U Latza; G Niedobitek; R Schwarting; H Nekarda; H Stein
Journal:  J Clin Pathol       Date:  1990-03       Impact factor: 3.411

7.  Analysis of pleural effusions using automated flow cytometry.

Authors:  K M Unger; M Raber; C W Bedrossian; D A Stein; B Barlogie
Journal:  Cancer       Date:  1983-09-01       Impact factor: 6.860

8.  A role for the Ca2(+)-dependent adhesion molecule, N-cadherin, in myoblast interaction during myogenesis.

Authors:  K A Knudsen; L Myers; S A McElwee
Journal:  Exp Cell Res       Date:  1990-06       Impact factor: 3.905

9.  Diagnostic value of DNA analysis in effusions by flow cytometry and image analysis. A prospective study on 102 patients as compared with cytologic examination.

Authors:  A Rijken; A Dekker; S Taylor; P Hoffman; M Blank; J R Krause
Journal:  Am J Clin Pathol       Date:  1991-01       Impact factor: 2.493

10.  Flow cytometry and Feulgen cytophotometry in evaluation of effusions.

Authors:  J Schneller; E Eppich; E Greenebaum; F Elequin; A Sherman; R Wersto; L G Koss
Journal:  Cancer       Date:  1987-04-01       Impact factor: 6.860

View more
  3 in total

1.  Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis.

Authors:  D Subirá; M Simó; J Illán; C Serrano; S Castañón; R Gonzalo; J J Granizo; M Martínez-García; M Navarro; J Pardo; J Bruna
Journal:  Clin Exp Metastasis       Date:  2015-03-21       Impact factor: 5.150

2.  Flow cytometry-based analysis of tumor-leukocyte ratios in peritoneal fluid from patients with advanced gastric cancer.

Authors:  Kazuya Takahashi; Kentaro Kurashina; Shin Saito; Rihito Kanamaru; Hideyuki Ohzawa; Hironori Yamaguchi; Hideyo Miyato; Yoshinori Hosoya; Alan Kawarai Lefor; Naohiro Sata; Joji Kitayama
Journal:  Cytometry B Clin Cytom       Date:  2020-12-04       Impact factor: 3.248

3.  Diagnostic accuracy of Ber-EP4 for metastatic adenocarcinoma in serous effusions: a meta-analysis.

Authors:  Bo Wang; Diandian Li; Xuemei Ou; Qun Yi; Yulin Feng
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.